Alzheimer's disease is a devasting illness with no effective treatment. But research is progressing rapidly and current clinical trials offer hope for a future disease-modifying therapy. In this week’s episode, I interview Dr. David Holtzman on the current state of Alzheimer’s research. We discuss his professional development as a physician scientist, his founding of the company C2N diagnostics, and his opinions on the current state and future of Alzheimer’s research. Dr. Holzman got his MD from Northwestern University and then completed a neurology residency and post-doctoral research at UCSF. He is the chairman of the neurology department at Washington University and is the scientific director of the Hope Center for Neurological Disorders. He is the Associate Director of the Knight ADRC and the president of the American Neurological Association.
Time stamps:
Disclosures:
Dr. Holtzman is the scientific co-founding member of C2N diagnostics. He has performed consulting work for Eli Lilly and Denali therapeutics. Brain Boy Neurology reports no relevant financial disclosures.
Non-epileptic seizures are difficult to diagnose and hard to treat. In this episode, we delve into the specifics of this disorder and discuss the...
Sleep deprivation is the norm in medical training. But does it have to be? I sit down with the Dr. Gabriela De Bruin to...
Seizures are the bread and butter of the neurological consult service. Gaining proficiency in the workup and management of first-time seizures makes a young...
